- Report
- May 2024
- 140 Pages
Global
From €6138EUR$6,499USD£5,220GBP
- Report
- May 2024
- 134 Pages
Global
From €6138EUR$6,499USD£5,220GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1180EUR$1,250USD£1,004GBP
- Report
- August 2020
- 80 Pages
Global
From €3069EUR$3,250USD£2,611GBP
- Report
- March 2024
- 200 Pages
Global
From €3919EUR$4,150USD£3,334GBP
- Report
- April 2025
- 50 Pages
Global
From €2503EUR$2,650USD£2,129GBP
Idebenone is a synthetic compound used in the treatment of central nervous system (CNS) disorders. It is a short-chain benzoquinone derivative that acts as an antioxidant and free radical scavenger. Idebenone is used to treat a variety of CNS disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). It is also used to treat mitochondrial diseases, such as Leigh syndrome, and to improve cognitive function in patients with dementia. Idebenone has been found to be effective in reducing the symptoms of these diseases, as well as improving cognitive function.
Idebenone is available in both oral and intravenous formulations. It is generally well tolerated, with few side effects. The most common side effects include nausea, vomiting, and diarrhea.
Idebenone is marketed by several companies, including Eisai, Merz Pharmaceuticals, and Teva Pharmaceuticals. It is also available as a generic drug. Show Less Read more